Hims & Hers Stock Plummets. The Wegovy Shortage Is Over.
The telehealth company has been selling a copycat version of a popular obesity drug during the recent shortage.
Hims & Hers shares tumble 18% as margin miss adds to concerns about GLP-1 business
Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...
Wegovy, Ozempic shortage declared over, hitting copycats like Hims & Hers
The ruling shows Novo Nordisk’s confidence that the supply of semaglutide will be stable for now.
HIMS Earnings: Shares Sink despite Smashing Guidance Estimates
Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...
Hims & Hers Shares Sink Despite Upbeat Earnings, Outlook
Shares of Hims & Hers Health fell, dragged down by expectations that the telehealth-consultation platform will have to stop selling its weight-loss treatments, which boosted results in the fourth ...
Fierce Healthcare10h
Hims & Hers projects weight loss business to hit $725M in 2025 despite GLP-1 market shift
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
Hims & Hers Declines - How The GLP-1 Market Shift Affects Growth
Hims & Hers plans to launch a generic version of liraglutide, but its efficacy is significantly lower than semaglutide. See ...
FDA says Ozempic and Wegovy shortage is ending. That’s bad news for this wellness stock.
We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.
Hims & Hers (HIMS) Sees 69% Revenue Increase Despite GLP-1 Uncertainties
Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...
MedCity News1d
Hims & Hers vs. Novo Nordisk: Are Compounded GLP-1s Safe?
Compounded GLP-1s have become more widespread, but are they safe? Some argue that compounding is nothing new, while others ...
Ozempic, Wegovy maker calls out Hims & Hers Super Bowl ad: ‘Check before you inject’
Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...
Stocks to Watch: Hims & Hers Health, Chegg, Wah Fu Education Group
Hims & Hers Health beat fourth-quarter estimates and guided for better-than-expected revenue in the first quarter and 2025. The telehealth provider logged earnings of 11 cents a share on revenue of ...